Identification | Back Directory | [Name]
Benzenesulfonamide, N-[2-(7-aminoheptyl)-1-(phenylmethyl)-1H-benzimidazol-5-yl]-2,4,6-trimethyl- | [CAS]
2871774-93-3 | [Synonyms]
JMV6944 Benzenesulfonamide, N-[2-(7-aminoheptyl)-1-(phenylmethyl)-1H-benzimidazol-5-yl]-2,4,6-trimethyl- | [Molecular Formula]
C30H38N4O2S | [MOL File]
2871774-93-3.mol | [Molecular Weight]
518.72 |
Hazard Information | Back Directory | [Uses]
JMV6944 is a PXR agonist. JMV6944 competitively inhibits hPXR ligand-binding domain (LBD) binding to PXR with an IC50 of 680nM. JMV6944 induces CYP3A4 mRNA expression in freshly isolated human primary human hepatocyte cultures. JMV6944 can be used for the synthesis of PROTAC PXR degrader JMV7048 (HY-162704)[1]. | [References]
[1] Bansard L, et al. A potent agonist-based PROTAC targeting Pregnane X Receptor that delays colon cancer relapse[J]. 2024. |
|
Company Name: |
Biorbyt Ltd.
|
Tel: |
+44 (0)1223 859 353 |
Website: |
http://www.biorbyt.com |
|